{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.99","value":"106.21"},{"comment":"As pre-specified in the SAP, data is not reported if the number of participants analyzed is less than 3.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"26.42","value":"43.15"},{"groupId":"OG003","spread":"49.61","value":"113.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"30.45","value":"51.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1, and Cycle 1 Day 8","title":"AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A","type":"SECONDARY","unitOfMeasure":"h*ug/mL"}